BIO Opposes Terms "Comparability" & "Therapeutic Equivalence" For Follow-On Biologics
This article was originally published in The Pink Sheet Daily
Executive Summary
The industry organization continues to emphasize the need for full clinical testing for follow-on biologics. BIO acknowledges that an abbreviated regulatory process may be possible in the future for certain follow-on products.